Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)

Market Cap	18.34B
Revenue (ttm)	2.84B
Net Income (ttm)	73.85M
Shares Out	1.12B
EPS (ttm)	0.06
PE Ratio	265.64
Forward PE	149.27
Dividend	0.09 (0.55%)
Ex-Dividend Date	Jun 6, 2025

Volume	11,858,888
Average Volume	22,516,646
Open	17.49
Previous Close	16.70
Day's Range	16.40 - 17.49
52-Week Range	13.10 - 23.45
Beta	0.95
RSI	34.69
Earnings Date	Oct 27, 2025

About SHE:300601

Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company’s marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, adsorbed, rabies vaccine (human diploid cell) for human use, hib conjugate vaccine, measles and rubella com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,913
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300601

Financial Performance

In 2024, SHE:300601's revenue was 2.65 billion, a decrease of -23.75% compared to the previous year's 3.48 billion. Earnings were 201.65 million, a decrease of -76.59%.